Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Stanford Medicine

Sites in Stanford & Palo Alto, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1359
Shown on this page
12
Current sort
Recently updated
Campus scope
Stanford Medicine, Stanford & Palo Alto, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Stanford Medicine, Stanford & Palo Alto, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 577–588 of 1,359 matching trials with a site at Stanford Medicine, Stanford & Palo Alto, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

NCT06001385
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Interventions
Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Post-Transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient Reported Outcomes, Melphalan, Total-body irradiation, Cyclophosphamide
Drug · Procedure · Other + 1 more
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Recruiting Phase 3 Interventional

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05254743
Status at this site: Recruiting
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
Interventions
Pirtobrutinib, Ibrutinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
737 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
19
States / cities
Anaheim, California • Cerritos, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional

Descemet Endothelial Thickness Comparison Trial I

NCT05289661
Site status not listed — check the official record
View directory record Official record
Conditions
Fuchs
Interventions
Topical Ripasudil, Topical Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Palo Alto, California • Sacramento, California • Palm Beach Gardens, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

NCT07196644
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumors Harboring MET Amplification
Interventions
Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
18
States / cities
Beverly Hills, California • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

NCT06235151
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Copper Cu 64 PSMA I&T
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
43
States / cities
Homewood, Alabama • Little Rock, Arkansas • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Active, not recruiting Phase 1 Interventional

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT04013685
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
Interventions
Orca-T
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Recruiting Not applicable Interventional

Rapid Evacuation and Access of Cerebral Hemorrhage Trial

NCT06870812
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Stroke Hemorrhagic
Interventions
Surgical management, Medical Management
Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Not yet recruiting Not applicable Interventional

Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

NCT07216859
Site status not listed — check the official record
View directory record Official record
Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Interventions
AI-Enabled Identification (EchoNet-Liver)
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Pleasanton, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

NCT03871257
Site status not listed — check the official record
View directory record Official record
Conditions
Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Interventions
Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
125
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Active, not recruiting Not applicable Interventional

Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder

NCT03511534
Site status not listed — check the official record
View directory record Official record
Conditions
OCD
Interventions
Psychotherapy, Pharmacotherapy
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Recruiting Phase 2 Interventional

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345
Status at this site: Recruiting
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex
Interventions
5% TolaSure Topical Gel, Topical Placebo Gel
Drug
Lead sponsor
BioMendics, LLC
Industry
Eligibility
2 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 11:23 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Neural Mechanisms of Decision Making in Hoarding Disorder

NCT03487224
Site status not listed — check the official record
View directory record Official record
Conditions
Hoarding Disorder
Interventions
MRI with fMRI frequency
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 11:23 AM EDT

About this Stanford Medicine institution page

What this page lists
ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Stanford University at any site, browse by condition, or browse by U.S. city.